ClinicalTrials.gg
RecruitingNCT07662109Eluminate-5Updated Oct 30, 2026

A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus

A Phase 3 interventional study of Elecoglipron and Dapagliflozin in Type 2 Diabetes Mellitus, sponsored by AstraZeneca. Recruiting at 303 sites in 24 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.
Updated Oct 30, 2026First site in SlovakiaSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,000
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing elecoglipron in Diabetes Mellitus, Type 2 — 6 open to participants now, 7 under way, 6 of them phase 3. elecoglipron · Diabetes Mellitus, Type 2.

Planned enrollment
Largest of 18
2,000 · median 57
Started
2026
with 8 others
Phase 3
6 of 18
6 open now
Registered
13th of 18
by date
Lead sponsor
14 of 18
AstraZeneca

Among the 18 studies testing elecoglipron in Diabetes Mellitus, Type 2, this one has the largest planned enrollment, is one of 9 that started in 2026, is one of 6 in phase 3, and was the 13th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

6 of the 18 studies testing elecoglipron in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About elecoglipron

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing elecoglipron in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron and dapagliflozin in combination, compared with elecoglipron alone and dapagliflozin alone, in adults with type 2 diabetes mellitus (T2DM) inadequately managed with lifestyle management alone or treated with other background glucose-lowering medication.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with Type 2 Diabetes Mellitus (T2DM) for at least 90 days prior to screening
  • T2DM inadequately managed with lifestyle management alone or on stable treatment with other background glucose-lowering medication
  • value of ≥ 7% to ≤ 10.5% (53 to 91.3 mmol/mol)
  • (BMI) of ≥ 23 kg/m2 at screening
  • Stable body weight (self-reported or documented) for 90 days prior to screening

Exclusion criteria

Exclusion Criteria:

  • Type 1 Diabetes, secondary forms of diabetes (including congenital forms), or history of ketoacidosis or hyperosmolar coma
  • Currently receiving or anticipated to receive, therapeutic intervention for diabetic retinopathy and/or macular edema
  • Have had more than one episode of severe hypoglycemia within 180 days prior to screening or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms
  • condition affecting the upper GI tract or chronic use of any medication that affects gastric motility or gastric emptying
  • History of acute or chronic pancreatitis
  • Severe congestive heart failure ( IV)
  • History/family history of medullary thyroid cancer or multiple endocrine neoplasia type 2
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
2,000 participants (estimated)

Study arms

  • Experimental
    Elecoglipron dose level 1 + dapagliflozin

    Participants will receive elecoglipron at dose level 1 and dapagliflozin, administered orally once daily.

    Drug: Elecoglipron · Drug: Dapagliflozin

  • Experimental
    Elecoglipron dose level 2 + dapagliflozin

    Participants will receive elecoglipron at dose level 2 and dapagliflozin, administered orally once daily.

    Drug: Elecoglipron · Drug: Dapagliflozin

  • Experimental
    Elecoglipron dose level 1 + dapagliflozin-matched placebo

    Participants will receive elecoglipron at dose level 1 and dapagliflozin-matched placebo, administered orally once daily.

    Drug: Elecoglipron · Drug: Dapagliflozin-matched placebo

  • Experimental
    Elecoglipron dose level 2 + dapagliflozin-matched placebo

    Participants will receive elecoglipron at dose level 2 and dapagliflozin-matched placebo, administered orally once daily.

    Drug: Elecoglipron · Drug: Dapagliflozin-matched placebo

  • Active comparator
    Elecoglipron-matched placebo + dapagliflozin

    Participants will receive elecoglipron-matched placebo + dapagliflozin, administered orally once daily.

    Drug: Dapagliflozin · Drug: Elecoglipron-matched placebo

Interventions

  • Elecoglipron is administered orally once daily.

  • Dapagliflozin administered orally once daily.

  • DrugElecoglipron-matched placebo

    A placebo matching elecoglipron administered orally once daily.

  • DrugDapagliflozin-matched placebo

    A placebo matching dapagliflozin administered orally once daily.

06

What researchers measure

Primary outcomes

  1. Change from baseline in Hemoglobin A1c (HbA1c)

    Time frame: Baseline to Week 40

Secondary outcomes

  1. Change from baseline in Hemoglobin A1c (HbA1c)

    Time frame: Baseline to Week 40

  2. Achievement of HbA1c < 7% (53 mmol/mol)

    Time frame: Week 40

  3. Percent change in body weight

    Time frame: Baseline to Week 40

  4. Change from baseline in body weight

    Time frame: Baseline to Week 40

  5. Change from baseline in Fasting Plasma Glucose (FPG)

    Time frame: Baseline to Week 40

  6. Change from baseline in daily mean 7-point Self-Monitored Blood Glucose (SMBG)

    Time frame: Baseline to Week 40

  7. Achievement of ≥ 5% weight loss from baseline

    Time frame: Baseline to Week 40

  8. Change from baseline in Systolic Blood Pressure (SBP)

    Time frame: Baseline to Week 40

  9. Change from baseline in Diastolic Blood Pressure (DBP)

    Time frame: Baseline to Week 40

  10. Time to initiation of rescue medication over 40 weeks

    Time frame: Baseline to Week 40

07

Study locations

116 of 303 sites recruiting
  • Research Site
    Huntsville, Alabama 35801, United States
    Not yet recruiting
  • Research Site
    Mobile, Alabama 36608, United States
    Not yet recruiting
  • Research Site
    Sheffield, Alabama 35660, United States
    Not yet recruiting
  • Research Site
    Little Rock, Arkansas 72205, United States
    Recruiting
  • Research Site
    Bakersfield, California 93309, United States
    Not yet recruiting
  • Research Site
    Los Angeles, California 90017, United States
    Recruiting
  • Research Site
    Ontario, California 91762, United States
    Not yet recruiting
  • Research Site
    Lake City, Florida 32055, United States
    Recruiting
  • Research Site
    Lakeland, Florida 33813, United States
    Recruiting
  • Research Site
    Atlanta, Georgia 30315, United States
    Not yet recruiting
  • Research Site
    Chicago, Illinois 60640, United States
    Recruiting
  • Research Site
    Skokie, Illinois 60077, United States
    Not yet recruiting
  • Research Site
    Evansville, Indiana 47714, United States
    Not yet recruiting
  • Research Site
    Sioux City, Iowa 51106, United States
    Not yet recruiting
  • Research Site
    Zachary, Louisiana 70791, United States
    Not yet recruiting
  • Research Site
    Annapolis, Maryland 21401, United States
    Not yet recruiting
  • Research Site
    Lutherville-Timonium, Maryland 21093, United States
    Not yet recruiting
  • Research Site
    Oxon Hill, Maryland 20745, United States
    Recruiting
  • Research Site
    Boston, Massachusetts 02114, United States
    Not yet recruiting
  • Research Site
    Boston, Massachusetts 02115, United States
    Not yet recruiting
  • Research Site
    Troy, Michigan 48098, United States
    Recruiting
  • Research Site
    Ridgeland, Mississippi 39157, United States
    Recruiting
  • Research Site
    Elkhorn, Nebraska 68022, United States
    Not yet recruiting
  • Research Site
    Toms River, New Jersey 08755, United States
    Not yet recruiting
  • Research Site
    Albuquerque, New Mexico 87112, United States
    Recruiting
  • Research Site
    Brooklyn, New York 11201, United States
    Recruiting
  • Research Site
    Rosedale, New York 11422, United States
    Not yet recruiting
  • Research Site
    Raleigh, North Carolina 27607, United States
    Not yet recruiting
  • Research Site
    Beachwood, Ohio 44122, United States
    Not yet recruiting
  • Research Site
    Maumee, Ohio 43537, United States
    Recruiting
  • Research Site
    Norman, Oklahoma 73069, United States
    Not yet recruiting
  • Research Site
    Philadelphia, Pennsylvania 19114, United States
    Not yet recruiting
  • Research Site
    Kingsport, Tennessee 37660, United States
    Recruiting
  • Research Site
    Nashville, Tennessee 37203, United States
    Recruiting
  • Research Site
    Dallas, Texas 75230, United States
    Recruiting
  • Research Site
    McKinney, Texas 75069, United States
    Not yet recruiting
  • Research Site
    Paris, Texas 75462, United States
    Recruiting
  • Research Site
    San Antonio, Texas 78258, United States
    Not yet recruiting
  • Research Site
    Webster, Texas 77598, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Layton, Utah 84041, United States
    Not yet recruiting
  • Research Site
    South Jordan, Utah 84095, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Newport News, Virginia 23606, United States
    Recruiting
  • Research Site
    Vienna, Virginia 22182, United States
    Not yet recruiting
  • Research Site
    Redmond, Washington 98052, United States
    Not yet recruiting
  • Research Site
    Kingwood, West Virginia 26537, United States
    Recruiting
  • Research Site
    Buenos Aires, C1012AAR, Argentina
    Not yet recruiting
  • Research Site
    Buenos Aires, C1120AAC, Argentina
    Recruiting
  • Research Site
    Buenos Aires, C1425AGC, Argentina
    Not yet recruiting
  • Research Site
    Caba, C1128AAF, Argentina
    Not yet recruiting
  • Research Site
    Ciudad de Buenos Aires, C1094AAD, Argentina
    Not yet recruiting
  • Research Site
    Mar del Plata, B7600GNY, Argentina
    Not yet recruiting
  • Research Site
    Rosario, S2000CVD, Argentina
    Not yet recruiting
  • Research Site
    San Nicolás, B2900DMH, Argentina
    Not yet recruiting
  • Research Site
    San Vicente, 5006, Argentina
    Not yet recruiting
  • Research Site
    Barretos, 14784-400, Brazil
    Not yet recruiting
  • Research Site
    Brasília, 71625-009, Brazil
    Not yet recruiting
  • Research Site
    Campinas, 13060-803, Brazil
    Not yet recruiting
  • Research Site
    Curitiba, 80030-480, Brazil
    Not yet recruiting
  • Research Site
    Fortaleza, 60426-000, Brazil
    Not yet recruiting
  • Research Site
    Natal, 59020-500, Brazil
    Recruiting
  • Research Site
    Porto Alegre, 90630-165, Brazil
    Not yet recruiting
  • Research Site
    Rio de Janeiro, 22270-060, Brazil
    Not yet recruiting
  • Research Site
    São José dos Campos, 12243-280, Brazil
    Not yet recruiting
  • Research Site
    São Paulo, 01228-200, Brazil
    Not yet recruiting
  • Research Site
    São Paulo, 04012-180, Brazil
    Not yet recruiting
  • Research Site
    Baotou, China
    Not yet recruiting
  • Research Site
    Beijing, 100044, China
    Recruiting
  • Research Site
    Beijing, 100050, China
    Not yet recruiting
  • Research Site
    Beijing, 102218, China
    Not yet recruiting
  • Research Site
    Changde, 415000, China
    Not yet recruiting
  • Research Site
    Changsha, 410015, China
    Recruiting
  • Research Site
    Changzhou, 272100, China
    Not yet recruiting
  • Research Site
    Chengdu, 610078, China
    Not yet recruiting
  • Research Site
    Chengdu, 611130, China
    Recruiting
  • Research Site
    Chenzhou, 423000, China
    Not yet recruiting
  • Research Site
    Chifeng, 024000, China
    Not yet recruiting
  • Research Site
    Hangzhou, 310014, China
    Not yet recruiting
  • Research Site
    Hefei, 230601, China
    Recruiting
  • Research Site
    Huai'an, 223005, China
    Recruiting
  • Research Site
    Jinan, 250031, China
    Recruiting
  • Research Site
    Jincheng, 048000, China
    Recruiting
  • Research Site
    Jining, 272006, China
    Not yet recruiting
  • Research Site
    Jinzhou Shi, 121001, China
    Recruiting
  • Research Site
    Kaifeng, 475000, China
    Recruiting
  • Research Site
    Langfang, 065000, China
    Not yet recruiting
  • Research Site
    Liangyugang, 222002, China
    Not yet recruiting
  • Research Site
    Luoyang, 471009, China
    Not yet recruiting
  • Research Site
    Meihekou, 135022, China
    Not yet recruiting
  • Research Site
    Nanjing, 210011, China
    Not yet recruiting
  • Research Site
    Nantong, 226001, China
    Not yet recruiting
  • Research Site
    Nanyang, 473009, China
    Recruiting
  • Research Site
    Pinggu, 101200, China
    Recruiting
  • Research Site
    Pingxiang, 337055, China
    Not yet recruiting
  • Research Site
    Sanya, 572000, China
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Shanghai, 200062, China
    Not yet recruiting
  • Research Site
    Shanghai, 201199, China
    Not yet recruiting
  • Research Site
    Shantou, 515065, China
    Not yet recruiting
  • Research Site
    Shenyang, 110004, China
    Not yet recruiting
  • Research Site
    Shenyang, 110023, China
    Recruiting
  • Research Site
    Shijiazhuang, 050000, China
    Not yet recruiting

Showing the first 100 of 303 sites across 24 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Jul 2028, 23 months after the start.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's planned 23 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2026
First posted
Jun 23, 2026
StartActual
Jul 6, 2026
Primary completionEst.
Jul 5, 2028
CompletionEst.
Jul 5, 2028
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
33 sites added, 2 sites removed — first site in Slovakia. 104 sites changed recruiting status (101 now recruiting, 2 now withdrawn, …)
Show 104 sites
  • Research Site · Little Rock, United StatesNot yet recruiting→Recruiting
  • Research Site · Los Angeles, United StatesNot yet recruiting→Recruiting
  • Research Site · Lake City, United StatesNot yet recruiting→Recruiting
  • Research Site · Lakeland, United StatesNot yet recruiting→Recruiting
  • Research Site · Chicago, United StatesNot yet recruiting→Recruiting
  • Research Site · Oxon Hill, United StatesNot yet recruiting→Recruiting
  • Research Site · Troy, United StatesNot yet recruiting→Recruiting
  • Research Site · Ridgeland, United StatesNot yet recruiting→Recruiting
  • Research Site · Albuquerque, United StatesNot yet recruiting→Recruiting
  • Research Site · Brooklyn, United StatesNot yet recruiting→Recruiting
  • Research Site · Maumee, United StatesNot yet recruiting→Recruiting
  • Research Site · Kingsport, United StatesNot yet recruiting→Recruiting
  • Research Site · Nashville, United StatesNot yet recruiting→Recruiting
  • Research Site · Dallas, United StatesNot yet recruiting→Recruiting
  • Research Site · Paris, United StatesNot yet recruiting→Recruiting
  • Research Site · Newport News, United StatesNot yet recruiting→Recruiting
  • Research Site · Kingwood, United StatesNot yet recruiting→Recruiting
  • Research Site · Buenos Aires, ArgentinaNot yet recruiting→Recruiting
  • Research Site · Natal, BrazilNot yet recruiting→Recruiting
  • Research Site · Beijing, ChinaNot yet recruiting→Recruiting
  • Research Site · Changsha, ChinaNot yet recruiting→Recruiting
  • Research Site · Chengdu, ChinaNot yet recruiting→Recruiting
  • Research Site · Hefei, ChinaNot yet recruiting→Recruiting
  • Research Site · Huai'an, ChinaNot yet recruiting→Recruiting
  • Research Site · Jinan, ChinaNot yet recruiting→Recruiting
  • Research Site · Jincheng, ChinaNot yet recruiting→Recruiting
  • Research Site · Jinzhou Shi, ChinaNot yet recruiting→Recruiting
  • Research Site · Kaifeng, ChinaNot yet recruiting→Recruiting
  • Research Site · Nanyang, ChinaNot yet recruiting→Recruiting
  • Research Site · Pinggu, ChinaNot yet recruiting→Recruiting
  • …and 74 more on the registry record
Show 33 added (8 Slovakia, 7 Japan, 7 Mexico, 6 United States, 4 South Korea, 1 Argentina)
  • Research Site · Toms River, United States
  • Research Site · Rosedale, United States
  • Research Site · Philadelphia, United States
  • Research Site · Webster, United States
  • Research Site · Layton, United States
  • Research Site · Vienna, United States
  • Research Site · Buenos Aires, Argentina
  • Research Site · Fukuoka, Japan
  • Research Site · Kamakura-shi, Japan
  • Research Site · Kamakura-shi, Japan
  • Research Site · Kitakyushu, Japan
  • Research Site · Soka-shi, Japan
  • Research Site · Tama-shi, Japan
  • Research Site · Yokohama, Japan
  • Research Site · Cuernavaca, Mexico
  • Research Site · Guadalajara, Mexico
  • Research Site · Guadalajara, Mexico
  • Research Site · Guadalajara, Mexico
  • Research Site · Monterrey, Mexico
  • Research Site · San Luis Potosí City, Mexico
  • Research Site · Zapopan, Mexico
  • Research Site · Bojnice, Slovakia
  • Research Site · Bratislava, Slovakia
  • Research Site · Lučenec, Slovakia
  • Research Site · Námestovo, Slovakia
  • Research Site · Rožňava, Slovakia
  • Research Site · Trebišov, Slovakia
  • Research Site · Vrútky, Slovakia
  • Research Site · Žilina, Slovakia
  • Research Site · Busan, South Korea
  • …and 3 more on the registry record
Show 2 removed
  • Research Site · Arlington, United States
  • Research Site · CABA, Argentina
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    33 sites added, 2 sites removed — first site in Slovakia. 112 sites changed recruiting status (109 now recruiting, 2 now withdrawn, …)
    Show 112 sites
    • Research Site · Little Rock, United StatesNot yet recruiting→Recruiting
    • Research Site · Los Angeles, United StatesNot yet recruiting→Recruiting
    • Research Site · Lake City, United StatesNot yet recruiting→Recruiting
    • Research Site · Lakeland, United StatesNot yet recruiting→Recruiting
    • Research Site · Chicago, United StatesNot yet recruiting→Recruiting
    • Research Site · Oxon Hill, United StatesNot yet recruiting→Recruiting
    • Research Site · Troy, United StatesNot yet recruiting→Recruiting
    • Research Site · Ridgeland, United StatesNot yet recruiting→Recruiting
    • Research Site · Albuquerque, United StatesNot yet recruiting→Recruiting
    • Research Site · Brooklyn, United StatesNot yet recruiting→Recruiting
    • Research Site · Maumee, United StatesNot yet recruiting→Recruiting
    • Research Site · Kingsport, United StatesNot yet recruiting→Recruiting
    • Research Site · Nashville, United StatesNot yet recruiting→Recruiting
    • Research Site · Dallas, United StatesNot yet recruiting→Recruiting
    • Research Site · Paris, United StatesNot yet recruiting→Recruiting
    • Research Site · Newport News, United StatesNot yet recruiting→Recruiting
    • Research Site · Kingwood, United StatesNot yet recruiting→Recruiting
    • Research Site · Buenos Aires, ArgentinaNot yet recruiting→Recruiting
    • Research Site · Natal, BrazilNot yet recruiting→Recruiting
    • Research Site · Beijing, ChinaNot yet recruiting→Recruiting
    • Research Site · Changsha, ChinaNot yet recruiting→Recruiting
    • Research Site · Chengdu, ChinaNot yet recruiting→Recruiting
    • Research Site · Hefei, ChinaNot yet recruiting→Recruiting
    • Research Site · Huai'an, ChinaNot yet recruiting→Recruiting
    • Research Site · Jinan, ChinaNot yet recruiting→Recruiting
    • Research Site · Jincheng, ChinaNot yet recruiting→Recruiting
    • Research Site · Jinzhou Shi, ChinaNot yet recruiting→Recruiting
    • Research Site · Kaifeng, ChinaNot yet recruiting→Recruiting
    • Research Site · Nanyang, ChinaNot yet recruiting→Recruiting
    • Research Site · Pinggu, ChinaNot yet recruiting→Recruiting
    • …and 82 more on the registry record
    Show 33 added (8 Slovakia, 7 Japan, 7 Mexico, 6 United States, 4 South Korea, 1 Argentina)
    • Research Site · Toms River, United States
    • Research Site · Rosedale, United States
    • Research Site · Philadelphia, United States
    • Research Site · Webster, United States
    • Research Site · Layton, United States
    • Research Site · Vienna, United States
    • Research Site · Buenos Aires, Argentina
    • Research Site · Fukuoka, Japan
    • Research Site · Kamakura-shi, Japan
    • Research Site · Kamakura-shi, Japan
    • Research Site · Kitakyushu, Japan
    • Research Site · Soka-shi, Japan
    • Research Site · Tama-shi, Japan
    • Research Site · Yokohama, Japan
    • Research Site · Cuernavaca, Mexico
    • Research Site · Guadalajara, Mexico
    • Research Site · Guadalajara, Mexico
    • Research Site · Guadalajara, Mexico
    • Research Site · Monterrey, Mexico
    • Research Site · San Luis Potosí City, Mexico
    • Research Site · Zapopan, Mexico
    • Research Site · Bojnice, Slovakia
    • Research Site · Bratislava, Slovakia
    • Research Site · Lučenec, Slovakia
    • Research Site · Námestovo, Slovakia
    • Research Site · Rožňava, Slovakia
    • Research Site · Trebišov, Slovakia
    • Research Site · Vrútky, Slovakia
    • Research Site · Žilina, Slovakia
    • Research Site · Busan, South Korea
    • …and 3 more on the registry record
    Show 2 removed
    • Research Site · Arlington, United States
    • Research Site · CABA, Argentina
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07662109
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jun 23, 2026
Start date
Jul 6, 2026
Primary completion
Jul 5, 2028 (estimated)
Completion
Jul 5, 2028 (estimated)
Last update
Oct 30, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Elecoglipron · Dapagliflozin

Start the discussion